BioMimetic Therapeutics, Inc. (BMTI) Posts Q3 Loss of 16c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Join SI Premium – FREE
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) reported Q3 EPS of ($0.16), $0.07 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $688.7 thousand versus the consensus estimate of $390 thousand.
For earnings history and earnings-related data on BioMimetic Therapeutics, Inc. (BMTI) click here.
For earnings history and earnings-related data on BioMimetic Therapeutics, Inc. (BMTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
- Neogen Corp. (NEOG) Tops Q1 EPS by 3c; raises guidance
- B.Riley Reiterates Buy Rating on Better Home & Finance Holding (BETR)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
